Expression of the genetic suppressor element 24.2 (GSE24.2) decreases DNA damage and oxidative stress in X-linked dyskeratosis congenita cells

PLoS One. 2014 Jul 2;9(7):e101424. doi: 10.1371/journal.pone.0101424. eCollection 2014.

Abstract

The predominant X-linked form of Dyskeratosis congenita results from mutations in DKC1, which encodes dyskerin, a protein required for ribosomal RNA modification that is also a component of the telomerase complex. We have previously found that expression of an internal fragment of dyskerin (GSE24.2) rescues telomerase activity in X-linked dyskeratosis congenita (X-DC) patient cells. Here we have found that an increased basal and induced DNA damage response occurred in X-DC cells in comparison with normal cells. DNA damage that is also localized in telomeres results in increased heterochromatin formation and senescence. Expression of a cDNA coding for GSE24.2 rescues both global and telomeric DNA damage. Furthermore, transfection of bacterial purified or a chemically synthesized GSE24.2 peptide is able to rescue basal DNA damage in X-DC cells. We have also observed an increase in oxidative stress in X-DC cells and expression of GSE24.2 was able to diminish it. Altogether our data indicated that supplying GSE24.2, either from a cDNA vector or as a peptide reduces the pathogenic effects of Dkc1 mutations and suggests a novel therapeutic approach.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Cycle Proteins / genetics*
  • Cell Line
  • DNA Damage*
  • Dyskeratosis Congenita / genetics*
  • Dyskeratosis Congenita / metabolism
  • Dyskeratosis Congenita / pathology
  • Dyskeratosis Congenita / therapy
  • Gene Expression Regulation*
  • Genetic Therapy
  • Heterochromatin / genetics
  • Heterochromatin / pathology
  • Humans
  • Mice
  • Nuclear Proteins / genetics*
  • Oxidative Stress*
  • Peptides / genetics
  • Peptides / therapeutic use
  • Telomere / genetics
  • Telomere / pathology
  • Transfection

Substances

  • Cell Cycle Proteins
  • DKC1 protein, human
  • Heterochromatin
  • Nuclear Proteins
  • Peptides

Grants and funding

This work was supported by grants: PI11-0949 and PI12/02263 FIS, SAF2008-01338 from the Ministerio de Ciencia e Innovación. Grants, PROMETEO2010/074 from Generalitat Valenciana and Fundación Salud 2000 to FVP. CMG, JLGG and CPQ are supported by CIBER de Enfermedades Raras. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.